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OBJECTIVE—Previous studies have indicated that the latent
autoimmune diabetes in adults (LADA) phenotype is heteroge-
neous and that LADA patients share features of type 1 and type
2 diabetes in various proportions. We tested for association of
known type 1 and type 2 diabetes susceptibility genes in LADA
subjects and analyzed relationships to a marker of autoimmune
activity (titers of anti-GAD) and a phenotypic risk factor of type
2 diabetes (BMI).
RESEARCH DESIGN AND METHODS—Data were assembled
from the Nord-Trøndelag Health Study (HUNT) study, which
comprises the adult population of an entire county in Norway.
We genotyped 60 single nucleotide polymorphisms (SNPs)
known to be associated with type 1 or type 2 diabetes, including
14 tag SNPs used for HLA haplotyping in 120 type 1 diabetic, 126
LADA, and 1,090 type 2 diabetic patients and 1,503 age- and
sex-matched nondiabetic subjects.
RESULTS—The majority of the strongly associated HLA haplo-
types for type 1 diabetes were signiﬁcantly associated with LADA
in general, but mainly with high anti-GAD LADA patients. Two
distinct HLA haplotypes were associated only with LADA and
mainly in low anti-GAD LADA patients. There were no associa-
tions of non-HLA type 1 diabetes loci with LADA. Of type 2
diabetes–associated genes, the CC/CT genotypes of rs7961581
(TSPAN8) and the obesity-linked AA/AC genotypes of rs8050136
(FTO) were associated with LADA in general, but mainly in low
anti-GAD LADA patients (P  0.004 and P  0.004, respectively).
CONCLUSIONS—Genetic heterogeneity in LADA is linked to
various degrees of autoimmune activity and may be partly
distinct from both type 1 and type 2 diabetes. Diabetes 59:
302–310, 2010
L
atent autoimmune diabetes in adults (LADA) is a
slowly progressive form of autoimmune-associ-
ated diabetes (1). It is a common form of diabe-
tes; for example, in the second Nord-Trøndelag
Health Study (HUNT2), 9% of diabetic patients were
classiﬁed as LADA (2). However, the etiology of LADA
remains less well understood than that of other forms of
diabetes.
It has been discussed whether LADA is a mild form of
type 1 diabetes or a distinct etiological entity (3–5).
Previous studies reported that LADA shares genetic fea-
tures with type 1 diabetes, including an increased fre-
quency of the HLA-DQB1 allele of the DQB1 gene (6,7).
However, other results show that age, obesity, and physi-
cal inactivity are important risk factors for both LADA and
type 2 diabetes (8). Furthermore, the type 2 diabetes–
associated gene TCF7L2 has been reported to be associ-
ated with LADA (9).
Thus, the etiology of LADA resembles partly type 1 and
partly type 2 diabetes. However, the genetic participation
of type 1 and type 2 diabetes susceptibility genes in the
etiology of LADA needs further elucidation and is compli-
cated by the phenotype of LADA being heterogeneous
among and within populations (5). The diagnosis of LADA
is usually based on the following: age older than 35 years,
the presence of at least one circulating autoantibody
against islet cell antigens (usually antibodies to GAD
[anti-GAD]), and no apparent need for insulin for at least 6
months after diagnosis. These criteria leave room for
heterogeneity. It has, for instance, been reported (10) that
the phenotype of individual LADA patients is related to
titer of anti-GAD, and in a recent study the need for insulin
treatment over several years was more frequent in those
with higher titers of anti-GAD (11).
In the present study, we ﬁrst investigated the associa-
tion of type 1 and type 2 diabetes candidate loci in LADA
patients in general. Second, we tested for variability in
genetic background in relation to a marker of autoimmune
activity (anti-GAD) as well as a phenotypic risk factor for
type 2 diabetes (BMI).
RESEARCH DESIGN AND METHODS
The HUNT2 study population. The second HUNT study, a population-based
study in Nord-Trøndelag County, was performed between 1995 and 1997.
Nord-Trøndelag is located in the central part of Norway and is fairly
demographically representative of Norway, making it suitable for epidemio-
logical studies. All inhabitants 20 years (n  92,936) were invited to
participate. The overall response rate was 71.3% (n  65,258). The survey
included a clinical examination, blood sampling, and two general question-
naires that included more than 200 health-related items. In addition, a speciﬁc
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Further details are described elsewhere (12).
Identiﬁcation of diabetic patients. Diabetic patients were identiﬁed by
self-reported answer of “yes” to the question “Do you have or have you had
diabetes?” (n  1972). Subjects answering “yes” were invited to a follow-up
examination where fasting C-peptide and anti-GAD were measured. In total,
73.6% participated (n  1,451). At follow-up, participants were also inter-
viewed by the screening nurses to ensure year of diagnosis and details on start
of different types of diabetes treatment (12).
C-peptide and anti-GAD measurements. Serum levels of C-peptide and
anti-GAD were analyzed at the Hormone Laboratory of Aker University
Hospital, Oslo, Norway. C-peptide was measured by radioimmunoassay
(Diagnostic System Laboratories, Webster, Texas) and anti-GAD by immuno-
precipitation using [
3H] leucine translation labeled GAD65 (Novo Nordisk
Pharma AS, Bagsvaerd, Denmark). The anti-GAD assay was based on a
validated method (13). Anti-GAD levels were expressed as an index value
relative to a standard serum, and a value 0.08 was considered positive. At the
cutoff level of 0.08, the assay was previously shown (2) by the Diabetes
Autoantibody Standardization Program (DASP) to have a sensitivity of 0.64
and speciﬁcity of 1.00.
Classiﬁcation of diabetes. Patients starting insulin treatment within 6
months of diagnosis were classiﬁed as type 1 diabetes if, in addition, they were
either anti-GAD positive or anti-GAD negative and had fasting C-peptide levels
150 pmol/l. Patients were classiﬁed as LADA if they were anti-GAD positive
and had not been treated with insulin within 12 months of diagnosis. Type 2
diabetic case subjects were anti-GAD negative and without insulin treatment
within 1 year of diagnosis. By these criteria, we included 120 type 1 diabetic,
126 LADA, and 1,090 type 2 diabetic patients in the present study. One
hundred ﬁfteen patients did not meet any of the criteria and were excluded.
Classiﬁcation of diabetic subjects not attending the follow-up exami-
nation. Not all the identiﬁed diabetic case subjects in HUNT2 attended the
follow-up examination (n  519). Nonattendees could therefore not be
classiﬁed by the criteria given above. Blood and serum samples in nonfasting
state were, however, available for 432 of these individuals in the HUNT
Biobank. Measuring anti-GAD from the serum samples combined with infor-
mation on age at diagnosis enabled us to classify these subjects by less
stringent criteria (i.e., as type 1 diabetic if anti-GAD positive and age at
diagnosis 35 years, as LADA if anti-GAD positive and age at diagnosis 35
years and as type 2 diabetic if anti-GAD negative and age of diagnosis 35
years). By these criteria, 16 subjects were classiﬁed as type 1 diabetic, 18 as
LADA, and 255 as type 2 diabetic patients. One hundred forty-three patients
did not meet any of these criteria and were therefore excluded.
Control subject group. Participants serving as control subjects (n  1,503)
were drawn from the same study. They answered “no” to the question of
having diabetes. They were frequency matched by sex and age (in years, by
decade) to the diabetic patients.
DNA extraction. DNA for genotyping was extracted from peripheral blood
leukocytes from EDTA whole blood or blood clots using the Gentra Purgene
blood kit (QIAGEN Science, Germantown, MD). This was done manually or by
automation with an Autopure LS (QIAGEN Science) mainly as described by
the manufacturer.
Genotyping. The selected single nucleotide polymorphisms (SNPs) were
based on publicly available results from type 1 (14–20) and type 2 (21–27)
diabetes studies. Genotyping was performed by applying TaqMan SNP allelic
discrimination using ABI 7900HT and by SNPlex genotyping system (Applied
Biosystems, Foster City, CA). Case and control subjects were equally distrib-
uted with four or more negative control subjects on each 384-plate. Criteria to
pass the assay were 1) call rates 90%, 2) minor allele frequency 1% in the
genotyped population, and 3) agreement with Hardy-Weinberg equilibrium in
the whole population, and if P value was 0.001 the assay did not pass. Assays
that did not pass quality control were excluded from further analysis.
HLA haplotyping. HLA haplotyping was performed as described by de
Bakker et al. (28). They captured nearby single tag SNPs or haplotypes of
combination of up to three SNPs as a predictor of known HLA alleles. The
recommended tag SNPs or haplotypes for the HLA risk alleles for type 1
diabetes are shown in supplementary Table 1 in the online appendix, which
is available at http://diabetes.diabetesjournals.org/cgi/content/full/db09-0923/
DC1. We genotyped these tag SNPs using SNPlex genotyping system.
Statistical analysis. PLINK software (http://pngu.mgh.harvard.edu/purcell/
plink/index.shtml) was used to assess whether genotypes were in Hardy-
Weinberg equilibrium and to test differences in genotype distribution between
affected and unaffected subjects by logistic regression under additive, domi-
nant, and recessive models. Odds ratios and 95% CIs were calculated.
Adjustment for diabetes-speciﬁc risk factors such as age, sex, and BMI was
applied when appropriate. Correction for multiple testing was done by max(T)
permutation where 1,000 permutations were performed. The nonparametric
Mann-Whitney U test was used to compare continuous variables between
groups using Statistical Package for the Social Sciences, version 14.0 (SPSS,
Chicago). A P value  0.05 was considered statistically signiﬁcant. Phasing
HLA haplotypes and testing for association within case and control subjects
were carried out using PLINK.
Ethics. All participants gave written consent. The study was approved by the
Regional Committee for Ethics in Medical Research and the Norwegian Data
Inspectorate.
RESULTS
Clinical characteristics. Age at onset was similar for
LADA and type 2 diabetic patients and lower for type 1
diabetic patients (Table 1). Overweight status, measured
by BMI and waist-to-hip ratios, was more marked in LADA
and type 2 diabetic than in type 1 diabetic and control
subjects. Relationships were similar for lipid parameters
and blood pressure.
Quality testing of SNPs. Forty-two prioritized SNPs
known to be associated with either type 1 or type 2
diabetes were genotyped on either TaqMan or SNPlex in
1,536 diabetic patients (106 additional patients were geno-
typed [TaqMan] for rs231775, rs689, rs2476601, and
rs3118470) from whom genomic DNA was available and in
1,503 nondiabetic control subjects. All SNPs were in
Hardy-Weinberg equilibrium (P  0.001) but two SNPs had
genotype call frequency 90% and were therefore ex-
TABLE 1
Phenotypic characteristics for male and female subjects selected from the HUNT cohort
LADA Type 1 diabetes Type 2 diabetes Control subjects
Male Female Male Female Male Female Male Female
n 68 58 72 48 534 556 740 763
Age when attended (years) 67  12 70  11 46  16 52  17 67  11 69  11 64  15 68  14
Age at diagnosis (years) 58  11 60  12 26  16 34  16 60  11 61  12
BMI (kg/m
2) 27.4  3.8 29.4  5.3 25.8  3.4 26.6  4.6 28.5  3.8 30.8  5.4 26.4  3.4 27.1  4.5
Waist-to-hip ratio 0.94  0.06 0.85  0.06 0.90  0.06 0.80  0.06 0.94  0.06 0.86  0.7 0.91  0.06 0.82  0.06
Cholesterol (mmol/l) 5.4  1.1 6.3  1.3 5.2  1.0 6.0  1.2 6.0  1.2 6.5  1.3 6.0  1.1 6.6  1.4
HDL cholesterol (mmol/l) 1.1  0.4 1.4  0.5 1.5  0.4 1.7  0.5 1.1  0.4 1.3  0.4 1.3  0.4 1.5  0.4
Triglycerides (mmol/l) 2.2  1.4 2.3  1.3 1.4  0.71 1.3  0.73 2.6  1.7 2.7  1.4 1.9  1.1 1.9  1.1
Systolic blood pressure
(mmHg) 154  21 154  26 140  20 141  25 152  23 160  24 146  21 151  26
Diastolic blood pressure
(mmHg) 85  12 80  14 79  10 78  12 86  13 86  14 84  12 83  14
Nonfasting glucose (mmol/l) 11  5.1 10.4  4.6 11  6.2 10.6  5.5 9.8  3.9 9.1  4.0 5.6  1.3 5.7  1.9
Data are means  SD.
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for the remaining SNPs was 98.6%.
A full statistical analysis including additive, dominant,
and recessive models of all the genotyped type 1 and type
2 diabetes risk loci is shown in supplementary Table 2 for
type 1 diabetic compared with control subjects, in supple-
mentary Table 3 for LADA compared with control sub-
jects, and in supplementary Table 4 for type 2 diabetic
compared with control subjects.
LADA in general: lack of association of non-HLA type
1 diabetes loci. We analyzed 12 SNPs within eight candi-
date risk loci for type 1 diabetes for association with 126
LADA patients. The CC genotype of rs3118470 in the
interleukin 2 receptor, alpha gene (IL2Ralfa) was associ-
ated with LADA (P  0.036), but the association became
less signiﬁcant (P  0.054) after adjustment for age, sex,
and BMI (Table 2). None of the other studied type 1
diabetes loci was associated with LADA.
LADA in general: association with type 2 diabetes
loci. For type 2 diabetes risk loci, we analyzed 28 SNPs
within 25 loci for association with LADA. The CC/CT
genotypes of rs7961581 upstream of the tetraspanin 8 gene
(TSPAN8) and the obesity-linked AA/AC genotypes of
rs8050136 in the fat mass and obesity–associated gene
(FTO) were associated with LADA (P  0.007 and P 
0.005, respectively) as well as type 2 diabetes (P  0.009
and P  0.005, respectively) (Table 3). Both loci remained
signiﬁcant after adjusting for age, sex, and BMI.
Veriﬁcation of associated SNPs. To verify associations
with LADA, we analyzed polymorphisms ﬂanking the SNPs
showing an association. We analyzed four additional SNPs
in the FTO gene (rs4389136 and rs1861866, 68 kb and 12 kb
downstream, respectively, and rs9931494 and rs2388405,
11 kb and 60 kb upstream, respectively) and two SNPs in
TSPAN8 (rs7306184, 45 kb downstream and rs7964431, 43
kb upstream) and in IL2R (rs9663421, 46 kb downstream
and rs4747880, 51 kb upstream). We selected SNPs with
essentially similar minor allele frequencies as the SNPs
initially showing an association. Two SNPs (rs7306184 and
rs4747880) were excluded from further analyses due to
low genotype call rate (90%).
The GG/GC genotypes of rs1861866 and TT/TC of
rs9931491 in the FTO gene were associated with both
LADA (P  0.001 and P  1.0  10
4, respectively) and
type 2 diabetes (P  0.047 and P  0.004, respectively),
and were still associated with LADA after adjustment for
age, sex, and BMI (Table 3). The association of rs9931491
with type 2 diabetes remained strong after adjustment for
age, sex, and BMI, however, the association of rs1861866
was lost. The SNP rs9931491 in the FTO gene was the only
SNP that remained signiﬁcantly associated with LADA
after adjusting for multiple testing with 1,000 permutations
(P  0.016). None of the other SNPs tested was associated
with LADA (supplementary Tables 2–4).
Association of genes in relation to BMI. We dichoto-
mized patients and control subjects on the basis of BMI 
(nonobese) or  (obese) 30 kg/m
2. The AA/AC genotypes
of rs8050136 in the FTO gene were signiﬁcantly associated
with obese LADA patients (P  0.024) (supplementary
Table 5). The two additional SNPs in the FTO gene, the
TT/TC genotypes of rs1861866 and the GG/GC genotypes
of rs9931494, were associated with both obese (P  0.048
and P  0.008, respectively) and nonobese (P  0.024 and
P  0.017, respectively) LADA patients. However, the
association of rs1861866 to obese LADA patients be-
came less signiﬁcant (P  0.054) after adjusting for age,
sex, and BMI.
The CC/CT genotypes of rs7961581 close to the TSPAN8
gene were associated with nonobese LADA patients (P 
0.003).
TABLE 2
Genotypes of known type 1 diabetes–associated loci in LADA and type 1 diabetic subjects compared with nondiabetic control
subjects
Gene name, SNP Genotype
LADA vs. control subjects Type 1 diabetic vs. control subjects
OR (95% CI) P* P† P‡ OR (95% CI) P* P† P‡
PTPN22, rs2476601 AA/AG GG 1.40 (0.92–2.12) 0.117 0.157 1 2.82 (1.92–4.13) 1.17  10
7 1.46  10
5 0.001
PTPN22, rs2488457 CC/CG GG 1.39 (0.95–2.03) 0.088 0.134 1 1.70 (1.15–2.50) 0.008 0.034 0.851
IL2R, rs3118470 CC CT/TT 1.62 (1.03–2.54) 0.036 0.054 1 1.09 (0.66–1.82) 0.732 0.614 1
INS, rs689 TT AA/AT 1.10 (0.76–1.59) 0.626 0.598 1 2.44 (1.60–3.71) 3.54  10
5 6.91  10
5 0.005
INS, rs3842753 CC AA/AC 1.18 (0.80–1.74) 0.396 0.368 1 2.38 (1.54–3.66) 8.63  10
5 1.89  10
4 0.011
*P value from logistic regression assuming dominant or recessive model. †Adjusted P value from logistic regression for age, sex, and BMI.
‡Empirical P value corrected for multiple testing by 1,000 permutations.
TABLE 3
Genotypes of known type 2 diabetes–associated loci in LADA and type 2 diabetic subjects compared with nondiabetic control
subjects
Gene name,
SNP Genotype
LADA vs. control subjects Type 2 diabetic vs. control subjects
OR (95% CI) P* P† P‡ OR (95% CI) P* P† P‡
TCF7L2,
rs7903146 CT/TT CC 1.25 (0.85–1.83) 0.252 0.141 1 1.75 (1.48–2.05) 1.89  10
11 4.84  10
14 0.001
TSPAN8/LGR5,
rs7961581 CC/CT TT 1.68 (1.15–2.46) 0.007 0.01 0.443 1.24 (1.06–1.46) 0.009 0.033 0.869
FTO, rs8050136 AA/AC CC 1.94 (1.22–3.09) 0.005 0.005 0.255 1.28 (1.08–1.53) 0.005 0.005 0.291
FTO, rs1861866 CT/TT CC 2.55 (1.45–4.50) 0.001 0.003 0.149 1.21 (1.00–1.46) 0.047 0.091 0.997
FTO, rs9931494 CG/GG CC 2.72 (1.63–4.53) 1.27  10
4 2.43  10
4 0.016 1.29 (1.09–1.54) 0.004 0.008 0.396
*P value from logistic regression assuming dominant model. †Adjusted P value from logistic regression for age, sex, and BMI. ‡Empirical P
value corrected for multiple testing by 1,000 permutations.
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cal characteristics. We dichotomized LADA on the basis
of anti-GAD levels below (low anti-GAD) or above (high
anti-GAD) the median of anti-GAD. Regarding the FTO
gene, the AA/AC genotypes of rs8050136, TT/TC genotypes
of rs1861866, and GG/GC genotypes of rs9931494 were
signiﬁcantly associated with low anti-GAD LADA (P 
0.004, P  0.004, and P  0.002, respectively) (supplemen-
tary Table 6). In addition, SNP rs9931494 was also associ-
ated with high anti-GAD LADA (P  0.020, supplementary
Table 7), but became less signiﬁcant (P  0.047) after
adjusting for age, sex, and BMI.
The genotypes CC/CT of rs7961581 close to the TSPAN8
gene were associated with low anti-GAD LADA (P  0.004).
Among clinical characteristics (Table 4), LADA patients
with high anti-GAD were younger at diagnosis (P  0.004)
and displayed shorter time to insulin treatment (P 
0.048). Further, fasting glucose was more elevated (P 
0.025) and fasting C-peptide more depressed (P  0.0007)
than in patients with low anti-GAD.
HLA haplotyping. Of 30 tag SNPs for HLA haplotyping, 18
were successfully genotyped. Of these, 14 could be used in
the prediction of HLA haplotypes (supplementary Table
8). The localization of these SNPs in the major histocom-
patibility complex (MHC) is depicted in Figure 1. The
majority of the strongly associated risk haplotypes for type
1 diabetes were also found to be signiﬁcant risk haplo-
types for LADA (supplementary Table 9). The frequency of
ACCCG haplotype for DRB1*0402-DQA1*0301-DQB1*0302
was increased in both LADA and type 1 diabetic patients
compared with control subjects (0.16 and 0.32 vs. 0.12, P 
0.036 and P  3.9  10
17, respectively) (Table 5). The
same was apparent with the GCCG haplotype for
DRB1*0401-DQA1*0301-DQB1*0302 (0.16 and 0.33 vs. 0.11,
P  0.028 and P  7.5  10
21), CT haplotype for
DRB1*0901-DQA1*0301-DQB1*0303 (0.23 and 0.36 vs. 0.16,
P  0.009 and P  9.2  10
14), AC haplotype for
DRB1*1,501-DQA1*0102-DQB1*0602 (0.41 and 0.5 vs. 0.33,
P  0.017 and P  5.3  10
7), and TAT haplotype for
DRB1*0701-DQA1*0201-DQB1*0303 (0.12 and 0.25 vs. 0.07,
P  0.015 and P  2.3  10
18). Interestingly, one distinct
haplotype GCA for DRB1*0401-DQA1*0301-DQB1*0301
was found to be associated with higher risk only for LADA
(0.09 vs. 0.05, P  0.013).
In general, the most strongly associated protective hap-
lotypes for type 1 diabetes were also found to be protec-
tive in LADA (supplementary Table 10). The frequency of
ATTG haplotype for DRB1*0401-DQA1*0301-DQB1*0302
was signiﬁcantly lower in both LADA and type 1 diabetic
patients compared with control subjects (0.18 and 0.06 vs.
0.25, P  0.014 and P  2.9  10
10, respectively) (Table
6). The same was observed for the TC haplotype for
DRB1*0902-DQA1*0301-DQB1*0303 (0.15 and 0.06 vs. 0.24,
P  0.003 and P  1.5  10
9), CT haplotype for
DRB1*1,501-DQA1*0102-DQB1*0602 (0.09 and 0.03 vs.
0.15, P  0.025 and P  1.7  10
6), and ATG haplotype
for DRB1*0401-DQA1*0301-DQB1*0301 (0.12 and 0.04 vs.
0.19, P  0.005 and P  8.3  10
9).
When dichotomizing LADA for high and low anti-GAD,
both the risk and protective HLA haplotypes described
above were now found to be associated with high anti-
GAD LADA patients (Tables 5 and 6), except the GCA
haplotype for DRB1*0401-DQA1*0301-DQB1*0301, which
was associated with higher risk in low anti-GAD LADA
patients (P  0.0003). Surprisingly, one more distinct
haplotype was found. The GCTA haplotype for
DRB1*0401-DQA1*0301-DQB1*0302 was associated with
higher risk only in low anti-GAD LADA (P  0.006) and not
with type 1 and type 2 diabetes.
Age at diagnosis of type 1 diabetes correlates with HLA
haplotype frequencies (29). Dichotomizing the type 1
diabetic patients on the basis of age of diagnosis at older
than or younger than 35 years enabled us to compare type
1 and LADA patients on a more equal age-at-onset basis.
We selected the average frequency from the seven stron-
gest associated risk HLA haplotypes and the average
frequency from the seven most protective HLA haplotypes
for type 1 diabetes to illustrate the differences in HLA
frequencies in different types of diabetes (Fig. 2). Risk
haplotype frequencies tended to decrease and protective
haplotype frequencies to increase when comparing pa-
tients and control subjects in the following order: early-
onset type 1 diabetic to late-onset type 1 diabetic through
high anti-GAD LADA and low anti-GAD LADA to type 2
diabetic and control subjects. This suggests a continuous
spectrum from strong to weak to nonexistent inﬂuence of
autoimmunity.
Including less stringently classiﬁed patients. The clin-
ical characteristics for the 18 patients who were classiﬁed
as LADA by less stringent criteria were mainly the same as
TABLE 4
Clinical characteristics of LADA patients displayed as low and high titers of anti-GAD
Clinical characteristics
Patients compared (n) Median (25th–75th percentile)
P* Low anti-GAD High anti-GAD Low anti-GAD High anti-GAD
Age at diagnosis (years) 65 61 62 (56–71) 56 (46–66) 0.004
Years with insulin treatment 16 27 6.0 (1.3–9.8) 6.0 (4.0–11) 0.605
Time to insulin dependence (years) 16 26 6.8 (4.3–12) 4.0 (2.9–7.0) 0.048
BMI (kg/m
2) 65 58 28 (26–31) 27 (25–31) 0.182
Waist-to-hip ratio 64 59 0.90 (0.85–0.96) 0.90 (0.85–0.93) 0.457
Cholesterol (mmol/l) 65 61 5.8 (5.2–6.7) 5.6 (4.8–6.6) 0.277
HDL cholesterol (mmol/l) 65 61 1.2 (0.9–1.5) 1.1 (0.9–1.5) 0.870
Triglycerides (mmol/l) 65 61 2.27 (1.22–2.98) 1.77 (1.12–2.66) 0.158
A1C 62 60 7.8 (6.4–9.4) 8.7 (7.1–10) 0.064
Systolic blood pressure (mmHg) 65 60 154 (143–174) 148 (132–170) 0.124
Diastolic blood pressure (mmHg) 65 60 82 (72–91) 81 (73–89) 0.861
Fasting glucose (mmol/l) 65 61 7.5 (6–8.9) 9.1 (6.9–10.6) 0.025
Fasting C-peptide (mmol/l) 65 61 697 (384–1,015) 334 (75–764.5) 0.0007
Data are median (25th–75th percentile) unless otherwise indicated. *P value from Mann-Whitney U test by comparing low and high anti-GAD
LADA patients.
E. PETTERSEN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JANUARY 2010 305patients characterized from the complete dataset (supple-
mentary Table 11). After including them in the analysis,
the type 1 diabetes–associated CC/CG genotypes of
rs2488457 in the protein tyrosine phosphatase nonreceptor
type 22 gene (PTPN22), CC genotype of rs2296336 in the
inositol 1,4,5-triphosphate receptor type 3 gene (ITPR3),
and the CC genotype of rs3118470 in the IL2R gene were
associated with LADA (P  0.039, P  0.008, and P 
0.008, respectively) (data not shown). The SNPs rs2296336
and rs3118470 remained signiﬁcant after adjusting for age,
sex, and BMI (P  0.015 and P  0.019, respectively),
however the rs2488457 showed only a trend (P  0.073)
after adjustment. The associations to the type 2 diabetes
loci TSPAN8 and FTO remained signiﬁcant, however, the
associations were slightly weakened. There were no dif-
ferences in the association of the FTO and TSPAN8 genes
to the dichotomized LADA patients. However, the type 1
diabetes–associated loci PTPN22 (rs2476601), ITPR3
(rs2296336), and IL2R (rs3118470) were now associated with
nonobese LADA patients (P  0.039, P  0.015, and P 
0.029, respectively) and high anti-GAD levels (P  0.034, P 
0.037, and P  0.011, respectively). The associated HLA
haplotypes with LADA became even stronger.
DISCUSSION
Our study indicates that in LADA patients 1) admixture of
both type 1 and type 2 diabetes–associated genetic vari-
ants are present, 2) heterogeneity is related to autoim-
mune activity as assessed by anti-GAD and insulin
resistance as assessed by BMI, and 3) there is suggestive
evidence for genetic associations that are not found in
either type 1 or type 2 diabetes.
Admixture of type 1 diabetes genes in LADA was
apparent for HLA haplotypes that confer risk for or
protection against type 1 diabetes. These ﬁndings are in
agreement with previous studies (9,30). In general, the
frequency of these haplotypes as well as signiﬁcance levels
were more pronounced for type 1 diabetes than for LADA,
although differences were attenuated when comparing late
age-at-onset type 1 diabetes and LADA (supplementary
Tables 9 and 10). On the other hand, type 1 diabetes genes
outside the HLA region were not in apparent association
with LADA. We found, as reported (31), strong associa-
tions between type 1 diabetes and SNPs rs689 and
rs3842753 in the insulin gene, whereas such associations
were lacking in LADA. Similar difference between type 1
diabetes and LADA were also noted for the genes PTPN22
and CTLA4 (supplementary Tables 2 and 3).
In regards to admixture of genes associated with type 2
diabetes, there was correspondence with LADA for the
FTO and TSPAN8/LGR5 genes. The association with FTO
and type 2 diabetes in the HUNT2 population was previ-
ously reported (32), whereas our ﬁnding in LADA patients
is novel. Notably, both the associations in type 2 diabetes
and in LADA patients remained after adjustment for BMI.
Such adjustment did in most (21,33) but not all (32,34)
other studies abolish the association with type 2 diabetes.
The high expression of the FTO gene in hypothalamus and
regulation by food intake suggests a role in controlling
energy homeostasis (35,36). However, underlying mecha-
nisms of inﬂuence in obesity and diabetes are not fully
elucidated. TSPAN8 is a member of the transmembrane 4
superfamily. Its role in the development of diabetes is still
unknown.
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those with low titers of anti-GAD and in those with high
BMI. An inverse relationship with autoimmune activity is
consistent with the absence of these SNP associations in
type 1 diabetes. Also, most of the HLA associations in
LADA patients were attenuated at lower versus higher
titers of anti-GAD. Relationships with BMI were generally
the inverse of those with anti-GAD. Collectively, our data
suggest a graded inﬂuence of the genetic predisposition
from a more type 1 diabetes–like one in those who exhibit
high autoimmune activity and lower BMI, toward a more
type 2 diabetes–like one in those that exhibit lower titers
of anti-GAD and higher BMI.
We did not conﬁrm an association between LADA and
the TCF7L2 gene (supplementary Table 3) that was re-
ported by Cervin et al. (9). The deﬁnition of LADA in the
study of Cervin et al. differs from ours, and there are
differences in the anthropometric data. However, we have
no clear-cut explanation for the discrepancy. One may
argue that our study was underpowered to detect an
impact of TCF7L2 in LADA. Still the high level of signiﬁ-
cance for association in type 2 diabetes (P  1.0  10
10,
TABLE 5
Frequency of the HLA haplotypes associated with higher risk in LADA and type 1 diabetes
Risk HLA haplotypes
Type 1 diabetes (n  119)
LADA
Total (n  121)
Anti-GAD 0.11
(n  56)
Anti-GAD 0.11
(n  65)
Frequency (n) P* Frequency (n) P* Frequency (n) P* Frequency (n) P*
DRB1*0402-DQA1*0301-
DQB1*0302
ACCCG 0.32 (38) 3.90  10
17 0.16 (20) 0.036 0.22 (13) 0.001 0.11 (7) 0.939
AACTG 0.34 (40) 0.023 0.33 (40) 0.065 0.37 (20) 0.037 0.3 (19) 0.527
DRB1*0401-DQA1*0301-
DQB1*0302
GCTA 0.02 (3) 0.847 0.04 (5) 0.107 0.01 (1) 0.341 0.07 (5) 0.002
GCCG 0.33 (40) 7.48  10
21 0.16 (19) 0.028 0.21 (12) 0.001 0.11 (7) 0.926
DRB1*0901-DQA1*0301-
DQB1*0303
CT 0.36 (43) 9.23  10
14 0.23 (27) 0.009 0.31 (17) 4.81  10
5 0.15 (10) 0.888
DRB1*1,501-DQA1*0102-
DQB1*0602
AC 0.50 (60) 5.31  10
7 0.41 (50) 0.017 0.41 (23) 0.105 0.42 (27) 0.069
DRB1*0701-DQA1*0201-
DQB1*0303
TAT 0.25 (30) 2.33  10
18 0.12 (14) 0.015 0.17 (10) 0.0002 0.07 (5) 0.962
DRB1*0401-DQA1*0301-
DQB1*0301
GCA 0.04 (5) 0.571 0.09 (11) 0.013 0.04 (2) 0.543 0.14 (9) 7.51  10
5
GCG 0.36 (43) 1.97  10
10 0.20 (25) 0.483 0.23 (13) 0.305 0.18 (12) 0.986
DRB1*0403-DQA1*0301-
DQB1*0302
CCGTG 0.13 (15) 7.57  10
12 0.05 (6) 0.179 0.08 (4) 0.016 0.03 (2) 0.692
*P value corrected for age, sex, and BMI.
TABLE 6
Frequency of the HLA haplotypes associated with protective effect in LADA and type 1 diabetes
Protective HLA
haplotypes
Type 1 diabetes (n  119)
LADA
Total (n  121)
Anti-GAD 0.11
(n  56)
Anti-GAD 0.11
(n  65)
Frequency (n) P* Frequency (n) P* Frequency (n) P* Frequency (n) P*
DRB1*0402-DQA1*0301-
DQB1*0302, TCTTG 0.03 (3) 0.0003 0.07 (9) 0.092 0.04 (2) 0.031 0.1 (7) 0.731
DRB1*0401-DQA1*0301-
DQB1*0302, ATTG 0.06 (7) 2.94  10
10 0.18 (21) 0.014 0.14 (8) 0.012 0.21 (14) 0.288
DRB1*0901-DQA1*0301-
DQB1*0303, TC 0.06 (7) 1.51  10
9 0.15 (18) 0.003 0.11 (6) 0.003 0.19 (12) 0.203
DRB1*1,501-DQA1*0102-
DQB1*0602, CT 0.03 (4) 1.73  10
6 0.09 (11) 0.025 0.06 (3) 0.014 0.12 (8) 0.418
DRB1*0701-DQA1*0201-
DQB1*0303, TGC 0.2 (24) 7.67  10
6 0.29 (35) 0.123 0.24 (13) 0.027 0.34 (22) 0.922
DRB1*0401-DQA1*0301-
DQB1*0301, ATG 0.04 (4) 8.28  10
9 0.12 (14) 0.005 0.1 (6) 0.017 0.13 (9) 0.093
DRB1*0403-DQA1*0301-
DQB1*0302, TTGTA 0.02 (2) 1.46  10
5 0.09 (11) 0.349 0.07 (4) 0.167 0.11 (7) 0.993
*P value corrected for age, sex, and BMI.
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of signiﬁcance in LADA. One could envisage that hetero-
geneity of LADA with regard to autoimmune activity
assessed by anti-GAD could obscure an association with
TCF7L2 in a subgroup with lower autoimmune activity.
However, we could not detect such an inﬂuence (supple-
mentary Table 6).
Our results provide some suggestive evidence for ge-
netic risk factors for LADA that are related to neither type
1 nor type 2 diabetes. The IL2R gene showed a trend
toward association with LADA but not with type 1 or type
2 diabetes. Also, two distinct HLA haplotypes were asso-
ciated only with LADA. These observations may serve as
pointers for studies that rigorously test the notion of partly
unique genetic predisposition for LADA.
A previous HUNT study (2) and a study in the U.K. (37),
demonstrated inverse relationships between anti-GAD ti-
ter and the odds ratio for effect of family history of
diabetes in LADA patients. This would suggest a strong
effect of nonautoimmune genes (most of which have yet to
been identiﬁed) in LADA patients.
Our study has limitations and strengths. An obvious
limitation is the relatively low number of patients in the
groups classiﬁed as type 1 diabetic and LADA. As a
consequence, the inability to obtain formal levels of sig-
niﬁcance for some gene associations may reside in lack of
power. Another potential weakness is the lack of complete
data on all professed diabetic patients. After retrospec-
tively analyzing anti-GAD in most of these individuals, we
could classify them into different forms of diabetes by
wider criteria than for those patients who were the main
focus of this study. By including these patients in some of
our analyses, we could estimate a possible bias occurring
from their exclusion. The “new” LADA patients were in
genetic terms perhaps more type 1 diabetes–like than the
average LADA patients in whom we had access to com-
plete data. However, including the new LADA patients in
our analysis did not materially change the conclusions that
were based on complete sets of data.
A technical limitation may pertain to anti-GAD measure-
ments, which were not compared with an alternative
method. However, our assay has been used and validated
previously (13). Furthermore, the outcome of a DASP
investigation indicates very high speciﬁcity of the assay
coupled with a lower sensitivity. The main concern here
could then be that we have missed some diabetic subjects
who, by other methods, could have been anti-GAD
positive.
Strengths of our study pertain to the HUNT studies
being all-population inclusive with a high attendance.
Notably our population-based group of adult type 1 diabe-
tes is rather unique because most other studies that
include type 1 diabetic subjects are based on hospital
records. Our data also indicate that the type 1 diabetic
subjects are representative outside a regional perspective.
Thus, data are in good agreement with published ones on
type 1 diabetes with regard to speciﬁc risk and protective
genes in white subjects and a diminished inﬂuence of
diabetes-associated HLA haplotypes with increasing age of
diagnosis (29). As to our type 2 diabetic and control
groups, they have previously been part of a replication in
a genome-wide association study (27) and other genetic
studies (32,38,39). The results of the HUNT part of these
previous studies showed in general good concordance
with other patient materials. The evidence that our study
is representative of both type 1 and type 2 diabetes should
increase the validity of comparisons with LADA.
In summary, we ﬁnd genetic resemblance to both type 1
and type 2 diabetes genes in LADA. Heterogeneity in
susceptibility genes in LADA is related to various degrees
of autoimmune activity and obesity. This highlights the
concept that it is the combined burden of risk factors that
brings on diabetes.
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